New adult ADHD drug receives FDA approval

Apr 24, 2008

The U.S. Food and Drug Administration has approved the first prodrug designed for once-daily treatment of adults with ADHD.

Although ADHD -- attention deficit-hyperactivity disorder -- is often thought of as a childhood malady, it's estimated 4.4 percent of U.S. adults ages 18-to-44 suffer from it. The new drug, Vyvanse, has been marketed in the United States since July 2007 for the treatment of ADHD in children 6-12 years of age.

The manufacturer, Shire PLC, a British-headquartered specialty biopharmaceutical company, said Vyvanse is the only once-daily prodrug stimulant approved to treat adults with ADHD. A prodrug is a medication designed to be inactive until it interacts with enzymes in the stomach, thereby making it difficult to be abused, a Shire spokesman said.

In a clinical study with adults, Vyvanse was shown to significantly improve ADHD symptoms, such as an inability to focus attention, hyperactivity and impulsivity, within the first week of use, Shire officials said.

The company said Vyvanse is now available in dosage strengths of 30 mg, 50 mg and 70 mg. Additional dosage strengths of 20 mg, 40 mg and 60 mg are expected to become available later this year.

Copyright 2008 by United Press International

Explore further: Zogenix says former obesity drug reduced seizures in study

Related Stories

More than two dozen articles provide insights on mummies

1 hour ago

In a special issue, The Anatomical Record ventures into the world of human mummified remains. In 26 articles, the anatomy of mummies is exquisitely detailed through cutting edge examination, while they are put in historical, archeo ...

Supercomputers a hidden power center of Silicon Valley

4 hours ago

Silicon Valley is famed for spawning the desktop, mobile and cloud computing revolutions. What is less well known is that it's one of the nerve centers for building the world's fastest number-crunchers.

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

May 22, 2015

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.